Acadian Asset Management
DNTH icon

Acadian Asset Management’s Dianthus Therapeutics DNTH Stock Holding History

Acadian Asset Management’s Portfolio DNTH Stock Details DNTH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-4,012
Closed -$120K – 1779
2024
Q1 		$120K Sell
4,012
-13,876
-78% -$302K ﹤0.01% 1259
2023
Q4 		$184K Sell
17,888
-4,411
-20% -$48.7K ﹤0.01% 1248
2023
Q3 		$303K Sell
22,299
-6,307
-22% -$79.5K ﹤0.01% 1115
2023
Q2 		$346K Sell
28,606
-9,782
-25% -$111K ﹤0.01% 1144
2023
Q1 		$486K Buy
38,388
+30,838
+408% +$341K ﹤0.01% 1057
2022
Q4 		$46K Buy
7,550
+1,610
+27% +$28.5K ﹤0.01% 1585
2022
Q3 		$132K Buy
5,940
+1,319
+29% +$36.1K ﹤0.01% 1295
2022
Q2 		$89K Buy
4,621
+3,416
+283% +$84.4K ﹤0.01% 1382
2022
Q1 		$55K Buy
1,205
+790
+190% +$43.2K ﹤0.01% 1454
2021
Q4 		$29K Buy
+415
New +$41.7K ﹤0.01% 1564

Other funds holding DNTH

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
RA Capital Management
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return

Acadian Asset Management's DNTH Position: Q2 2024 in Review

Acadian Asset Management sold out of Dianthus Therapeutics (DNTH) in Q2 2024, closing a stake of 4,012 shares — an estimated $120K sold.

Acadian Asset Management first reported a position in DNTH in Q4 2021 and held it in 10 quarters. The position peaked at $486K in Q1 2023. 74 funds tracked by Wall St. Rank hold DNTH as of Q2 2024.

  • Acadian Asset Management reported no remaining Dianthus Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Acadian Asset Management sold 4,012 Dianthus Therapeutics shares in Q2 2024, an estimated $120K.
  • Acadian Asset Management first reported a position in Dianthus Therapeutics in Q4 2021 and held it in 10 quarters.
  • Acadian Asset Management's Dianthus Therapeutics position peaked at $486K in Q1 2023.
  • 74 funds tracked by Wall St. Rank held Dianthus Therapeutics as of Q2 2024.

Based on Acadian Asset Management's 13F filing for Q2 2024, filed 6 Aug 2024.